PODXL, podocalyxin like, 5420

N. diseases: 156; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4024610
Disease: Leg muscle stiffness
Leg muscle stiffness 		0.100 Biomarker phenotype HPO
CUI: C4024929
Disease: Slowed slurred speech
Slowed slurred speech 		0.100 Biomarker phenotype HPO
CUI: C4551584
Disease: Brain atrophy
Brain atrophy 		0.100 Biomarker disease HPO
CUI: C4552855
Disease: Agitation, CTCAE 5.0
Agitation, CTCAE 5.0 		0.100 Biomarker phenotype HPO
CUI: C4553743
Disease: Spasticity, CTCAE
Spasticity, CTCAE 		0.100 Biomarker phenotype HPO
CUI: C0268731
Disease: Renal glomerular disease
Renal glomerular disease 		0.040 Biomarker group BEFREE Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man. 8600307 1996
CUI: C0027697
Disease: Nephritis
Nephritis 		0.010 Biomarker disease BEFREE Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man. 8600307 1996
CUI: C0027708
Disease: Nephroblastoma
Nephroblastoma 		0.040 Biomarker disease BEFREE The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. 15155752 2004
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.040 AlteredExpression group LHGDN Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. 15289306 2004
CUI: C0035078
Disease: Kidney Failure
Kidney Failure 		0.020 GeneticVariation disease BEFREE However, the data do suggest that Wt1 R394W-induced glomerulosclerosis may be independent of downregulation of the genes for NPHS1, NPHS2, CD2AP, and podocalyxin and may involve other genes yet to be implicated in renal failure. 15509792 2004
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.020 AlteredExpression phenotype BEFREE We propose that inappropriate expression of PODXL due to changes in WT1 and/or p53 activity may contribute to Wilms tumorigenesis. 15155752 2004
CUI: C1333015
Disease: Childhood Kidney Wilms Tumor
Childhood Kidney Wilms Tumor 		0.020 Biomarker disease BEFREE The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. 15155752 2004
CUI: C0178664
Disease: Glomerulosclerosis (disorder)
Glomerulosclerosis (disorder) 		0.010 GeneticVariation disease BEFREE However, the data do suggest that Wt1 R394W-induced glomerulosclerosis may be independent of downregulation of the genes for NPHS1, NPHS2, CD2AP, and podocalyxin and may involve other genes yet to be implicated in renal failure. 15509792 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 Biomarker disease CTD_human These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33. 16434482 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 Biomarker disease BEFREE These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33. 16434482 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.320 Biomarker group CTD_human Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. 16434482 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.320 GeneticVariation group LHGDN Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. 16434482 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.090 Biomarker group BEFREE These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33. 16434482 2006
CUI: C0022658
Disease: Kidney Diseases
Kidney Diseases 		0.030 Biomarker group BEFREE Platelet half-life and basic hemostatic parameters were unaffected in plt1/plt1 mice, and the thrombocytopenia and kidney disease were not attenuated on a lymphocyte-deficient rag1-null background. gpIbalpha and podocalyxin were found to be major underglycosylated proteins in plt1/plt1 platelets and the kidney, respectively, implying that these are key targets for C1GalT1, appropriate glycosylation of which is essential for platelet production and kidney function. 17062753 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.020 Biomarker disease BEFREE These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33. 16434482 2006
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE Since the initial discovery of podocalyxin in a cancerous stem cell, numerous new studies have identified podocalyxin in many different human cancers and in embryonic stem cells lines (ES) derived from human embryos. 17124010 2007
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.030 AlteredExpression group LHGDN Adenocarcinomas of the lung and prostate, and liver metastases of colorectal carcinomas lacked PODXL-1 expression. 17137615 2007
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma 		0.030 Biomarker disease BEFREE Our study determined the genes involved in early pathogenetic events of neoplastic germ cell formation, provided new insights into genetic pathways driving the transition of embryonal carcinoma and seminoma from IGCNU and identified new biomarkers of neoplastic germ cells such as CD9, CENPA and PODXL. 17970049 2007
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma 		0.030 Biomarker disease BEFREE We report here that purified podocalyxin from embryonal carcinoma has binding activity with the TRA-1-60 and TRA-1-81 antibodies. 17124010 2007
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma 		0.030 AlteredExpression disease LHGDN Thus, embryonal carcinoma expresses two distinct forms of podocalyxin, and the larger version is a molecular carrier of the human stem cell-defining antigens TRA-1-60 and TRA-1-81. 17124010 2007